← Leaderboards
Stephen D Hall
Indiana Univ-Purdue Univ At Indianapolis
$1,925,382
Attributed
$1,925,382
Total exposure
32
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $467.3K · FY2005–08$500K$375K$250K$125K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$1,925,382 · 32
By mechanism
R01$1,454,801 · 2
M01$470,581 · 30
Top collaborators
No co-investigators on record.
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Barbara Haehner$0
- Jude Christopher Gorski$1,202,478
- Christopher J Sweeney$4,398,891
Others in their field
Top investigators on “Cytochrome P450”
- Eric F Johnson · Scripps Research Institute$21,555,814
- Irina A Pikuleva · University Of Texas Medical Br Galveston$15,661,223
- Maria Almira Correia · University Of California San Francisco$15,613,829
- Bhagavatula Moorthy · Baylor College Of Medicine$14,960,433
- Kafait U Malik · University Of Tennessee Health Sci Ctr$14,014,312
- Michal Laniado Schwartzman · New York Medical College$13,763,631
Research focus
Cytochrome P450Human SubjectClinical ResearchMidazolamHuman Old Age (65+)Enzyme ActivityAge DifferenceDrug MetabolismUnited States National Institutes Of HealthResearch PersonnelSourceYoung Adult Human (21-34)FundingGrantInstitutionClinical TrialsComputer Retrieval Of Information On Scientific Projects DatabaseResourcesVolunteerPharmacokineticsDrug KineticsDrug InteractionsPharmaceutical PreparationsClearance Rate
Grant awards (69)
THE DISPOSITION OF ACETAMINOPHEN AND FEXOFENADINE ALONE AND IN COMBINATION IN HE$2,675
M01 · FY2008 · RR · contact PI
THE EFFECT OF CONCOMITANT ADMINISTRATION OF ERYTHROMYCIN AND DILTIAZEM ON CYP$1,774
M01 · FY2008 · RR · contact PI
THE EFFECT OF DOXYCYCLINE ON THE EFFICACY OF ORAL CONTRACEPTIVE PILLS$1,541
M01 · FY2008 · RR · contact PI
ONSET OF INHIBITORY EFFECT OF CLARITHROMYCIN ON HUMAN INTESTINAL CYTOCHROME P$422
M01 · FY2008 · RR · contact PI
ORAL ERYTHROMYCIN ON QT INTERVAL IN HEALTHY SUBJECTS, PATIENTS WITH CIRRHOSIS$233
M01 · FY2008 · RR · contact PI
EFFECT OF CLARITHROMYCIN ON THE ORAL CLEARANCE OF BUSPIRONE IN PATIENTS WITH$102
M01 · FY2008 · RR · contact PI
THE EFFECTS OF GENOTYPE ON DRUG RESPONSE$29
M01 · FY2008 · RR · contact PI
THE DISPOSITION OF ACETAMINOPHEN AND FEXOFENADINE ALONE AND IN COMBINATION IN HE$31,487
M01 · FY2007 · RR · contact PI
THE EFFECT OF CONCOMITANT ADMINISTRATION OF ERYTHROMYCIN AND DILTIAZEM ON CYP$20,879
M01 · FY2007 · RR · contact PI
THE EFFECT OF DOXYCYCLINE ON THE EFFICACY OF ORAL CONTRACEPTIVE PILLS$18,138
M01 · FY2007 · RR · contact PI
ONSET OF INHIBITORY EFFECT OF CLARITHROMYCIN ON HUMAN INTESTINAL CYTOCHROME P$4,963
M01 · FY2007 · RR · contact PI
ORAL ERYTHROMYCIN ON QT INTERVAL IN HEALTHY SUBJECTS, PATIENTS WITH CIRRHOSIS$2,737
M01 · FY2007 · RR · contact PI
EFFECT OF CLARITHROMYCIN ON THE ORAL CLEARANCE OF BUSPIRONE IN PATIENTS WITH$1,198
M01 · FY2007 · RR · contact PI
THE EFFECTS OF GENOTYPE ON DRUG RESPONSE$341
M01 · FY2007 · RR · contact PI
Effect of Cirrhosis and Shunts on Drug Disposition$279,605
R01 · FY2006 · DK · contact PI
THE EFFECT OF DOXYCYCLINE ON THE EFFICACY OF ORAL CONTRACEPTIVE PILLS$30,302
M01 · FY2006 · RR · contact PI
EFFECT OF MULTIPLE DOSES OF KETOCONAZOLE ON CYTOCHROME P450 3A ACTIVITY$16,767
M01 · FY2006 · RR · contact PI
CHRTAMOXIFEN RX ON CYTOCHROME P450 ACTIVITY & P-GLYCOPROTEIN TRANSPORT$11,313
M01 · FY2006 · RR · contact PI
ONSET OF INHIBITORY EFFECT OF CLARITHROMYCIN ON HUMAN INTESTINAL CYTOCHROME P$8,889
M01 · FY2006 · RR · contact PI
RELATIONSHIP BETWEEN CYP3A5 GENOTYPES AND EFFECT OF VERAPAMIL ON MIDAZOLAM$1,212
M01 · FY2006 · RR · contact PI
Aging Effects on Drug Bioavailability$281,307
R01 · FY2005 · GM
EFFECT OF MULTIPLE DOSES OF KETOCONAZOLE ON CYTOCHROME P450 3A ACTIVITY$80,848
M01 · FY2005 · RR
RELATIONSHIP BETWEEN CYP3A5 GENOTYPES AND EFFECT OF VERAPAMIL ON MIDAZOLAM$36,448
M01 · FY2005 · RR
THE EFFECT OF DOXYCYCLINE ON THE EFFICACY OF ORAL CONTRACEPTIVE PILLS$29,379
M01 · FY2005 · RR
THE EFFECT OF ECHINACEA ON THE EFFICACY OF ORAL CONTRACEPTION$24,299
M01 · FY2005 · RR
CHRTAMOXIFEN RX ON CYTOCHROME P450 ACTIVITY &P-GLYCOPROTEIN TRANSPORT$14,359
M01 · FY2005 · RR
THE EFFECTS OF GENOTYPE ON DRUG RESPONSE$663
M01 · FY2005 · RR
Aging Effects on Drug Bioavailability$295,710
R01 · FY2004 · GM
Relationship Between CYP3A5 Genotypes and Effect of Verapamil on Midazolam$60,804
M01 · FY2004 · RR
The Effect of Echinacea on the Efficacy of Oral Contraception$59,309
M01 · FY2004 · RR
Chr.Tamoxifen Rx on Cytochrome P450 Activity &P-Glycoprotein Transport$5,233
M01 · FY2004 · RR
The Effects of Genotype on Drug Response$4,237
M01 · FY2004 · RR
Aging Effects on Drug Bioavailability$295,710
R01 · FY2003 · GM
Aging Effects on Drug Bioavailability$302,469
R01 · FY2002 · GM
AGE/GENDER ON CLARITHROMYCIN CYP3A INHIBITION DURATION$0
M01 · FY2002 · RR
CONTRIBUTION OF INTESTINAL CYP3A TO FIRST PASS METABOLISM OF MIDAZOLAM$0
M01 · FY2002 · RR
EFFECT OF AGE AND GENDER ON CYP3A INDUCTION$0
M01 · FY2002 · RR
EFFECT OF AGE AND ESTROGEN REPLACEMENT THERAPY ON DRUG DISPOSITION$0
M01 · FY2002 · RR
TOLBUTAMIDE, CAFFEINE, DEXTROMETHORPHAN FOR P450 ACTIVIT$0
M01 · FY2002 · RR
CONTRIBUTION OF INTESTINAL CYP3A TO FIRST PASS METABOLISM OF MIDAZOLAM$0
M01 · FY2001 · RR
AGE/GENDER ON CLARITHROMYCIN CYP3A INHIBITION DURATION$0
M01 · FY2001 · RR
TOLBUTAMIDE, CAFFEINE, DEXTROMETHORPHAN FOR P450 ACTIVIT$0
M01 · FY2001 · RR
EFFECT OF AGE AND ESTROGEN REPLACEMENT THERAPY ON DRUG DISPOSITION$0
M01 · FY2001 · RR
EFFECT OF AGE AND GENDER ON CYP3A INDUCTION$0
M01 · FY2001 · RR
AGE/GENDER ON CLARITHROMYCIN CYP3A INHIBITION DURATION$0
M01 · FY2000 · RR
TOLBUTAMIDE, CAFFEINE, DEXTROMETHORPHAN FOR P450 ACTIVIT$0
M01 · FY2000 · RR
TOLBUTAMIDE, CAFFEINE, DEXTROMETHORPHAN FOR P450 ACTIVIT$0
M01 · FY2000 · RR
TOLBUTAMIDE, CAFFEINE, DEXTROMETHORPHAN FOR P450 ACTIVIT$0
M01 · FY2000 · RR
TOLBUTAMIDE, CAFFEINE, DEXTROMETHORPHAN FOR P450 ACTIVIT$0
M01 · FY2000 · RR
TOLBUTAMIDE, CAFFEINE, DEXTROMETHORPHAN FOR P450 ACTIVIT$0
M01 · FY2000 · RR
EFFECT OF AGE AND ESTROGEN REPLACEMENT THERAPY ON DRUG DISPOSITION$0
M01 · FY2000 · RR
EFFECT OF AGE AND ESTROGEN REPLACEMENT THERAPY ON DRUG DISPOSITION$0
M01 · FY2000 · RR
EFFECT OF AGE AND ESTROGEN REPLACEMENT THERAPY ON DRUG DISPOSITION$0
M01 · FY2000 · RR
EFFECT OF AGE AND ESTROGEN REPLACEMENT THERAPY ON DRUG DISPOSITION$0
M01 · FY2000 · RR
EFFECT OF AGE AND ESTROGEN REPLACEMENT THERAPY ON DRUG DISPOSITION$0
M01 · FY2000 · RR
EFFECT OF AGE AND GENDER ON CYP3A INDUCTION$0
M01 · FY2000 · RR
EFFECT OF AGE AND GENDER ON CYP3A INDUCTION$0
M01 · FY2000 · RR
EFFECT OF AGE AND GENDER ON CYP3A INDUCTION$0
M01 · FY2000 · RR
EFFECT OF AGE AND GENDER ON CYP3A INDUCTION$0
M01 · FY2000 · RR
EFFECT OF AGE AND GENDER ON CYP3A INDUCTION$0
M01 · FY2000 · RR
CONTRIBUTION OF INTESTINAL CYP3A TO FIRST PASS METABOLISM OF MIDAZOLAM$0
M01 · FY2000 · RR
CONTRIBUTION OF INTESTINAL CYP3A TO FIRST PASS METABOLISM OF MIDAZOLAM$0
M01 · FY2000 · RR
CONTRIBUTION OF INTESTINAL CYP3A TO FIRST PASS METABOLISM OF MIDAZOLAM$0
M01 · FY2000 · RR
CONTRIBUTION OF INTESTINAL CYP3A TO FIRST PASS METABOLISM OF MIDAZOLAM$0
M01 · FY2000 · RR
CONTRIBUTION OF INTESTINAL CYP3A TO FIRST PASS METABOLISM OF MIDAZOLAM$0
M01 · FY2000 · RR
AGE/GENDER ON CLARITHROMYCIN CYP3A INHIBITION DURATION$0
M01 · FY2000 · RR
AGE/GENDER ON CLARITHROMYCIN CYP3A INHIBITION DURATION$0
M01 · FY2000 · RR
AGE/GENDER ON CLARITHROMYCIN CYP3A INHIBITION DURATION$0
M01 · FY2000 · RR
AGE/GENDER ON CLARITHROMYCIN CYP3A INHIBITION DURATION$0
M01 · FY2000 · RR